03465nas a2200397   4500008004100000022002500041245010800066210006900174260001700243300001600260490000700276520217500283653001002458653003602468653001102504653002202515653001102537653004902548653004502597653000902642653003402651653003502685653001702720653006902737653003902806653002202845653004002867100001702907700001402924700002002938700001702958700001302975700001702988700001703005856004503022       2001                        eng d  a0931-0509; 0931-050900aImpact of schistosomiasis on patient and graft outcome after renal transplantation: 10 years' follow-up0 aImpact of schistosomiasis on patient and graft outcome after ren  aEnglandcNov  a2214 - 22210 v163 aBACKGROUND: Schistosomiasis is a major health problem in some areas of the world. Schistosomal-specific nephropathy is a well-known occurrence and eventually leads to end-stage renal failure. Patients with schistosomal infection were considered to be suitable recipients for renal transplantation. However, the long-term impact of schistosomiasis on kidney transplantation is not yet been reported. METHODS: The long-term impact of schistosomiasis on patient and graft outcomes was studied by comparing two groups of subjects from a total of 243 patients. Group I consisted of cases with schistosomal infections and group II consisted of schistosoma-free controls. Schistosomiasis was documented in group I by identifying schistosoma eggs in urine, stool or rectal mucosal biopsy. Also intra-operative biopsies from bladder mucosa of the graft recipients and from the lower end of the ureter of living donors were obtained to search for schistosoma eggs. RESULTS: Sixty-three cases of schistosomiasis were diagnosed in both recipients and donors, 65 cases in recipients only, and eight cases in donors only. Infected recipients and donors with active lesions were treated at least 1 month before transplantation by combined antischistosomal drugs (praziquantel and oxamniquine). The 243 patients (136 schistosoma-infected cases and 107 controls) were followed regularly for a period of 10 years after transplantation. We found that there was no significant difference in the incidence of acute and chronic rejection between the groups; however, higher cyclosporin doses were needed for the infected group with subsequent higher incidence of both acute and chronic cyclosporin nephrotoxicity. Moreover, the schistosomal group had a significantly higher incidence of urinary tract infection and urological complications with no evidence of schistosomal re-infection. CONCLUSIONS: Despite a higher incidence of schistosoma-related complications after renal transplantation, schistosomal infection is not a major risk factor for transplantation. Therefore, infected patients can be considered as suitable recipients if they have been properly treated before transplantation.10aAdult10aAnthelmintics / therapeutic use10aFemale10aFollow-Up Studies10aHumans10aKidney Failure, Chronic / etiology / surgery10aKidney Transplantation / adverse effects10aMale10aOxamniquine / therapeutic use10aPraziquantel / therapeutic use10aRisk Factors10aSchistosomiasis / complications / drug therapy / physiopathology10aSchistosomicides / therapeutic use10aTreatment Outcome10aUrinary Tract Infections / etiology1 aMahmoud, K M1 aSobh, M A1 aEl-Agroudy, A E1 aMostafa, F E1 aBaz, M E1 aShokeir, A A1 aGhoneim, M A  uhttp://613633.bywedr.asia/reference/1719